Knee Replacement News and Research

RSS

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

22 Jun 2012

UCSF's ACT program helps amputees reach their athletic goals

Carlos Gonzalez stands out from an athletic group gathered on a grassy field at the UCSF Mission Bay campus. The gregarious 32-year-old sports a stylish fauxhawk and walks with a confident yet understated swagger. He's training to become a mixed martial arts (MMA) fighter.

6 Jun 2012

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

ThromboGenics NV and co-development partner BioInvent International announce today the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban, an oral anticoagulant.

5 Jun 2012

Arthritis rates set to soar

According to new estimates the number of people with arthritis is set to soar with predictions that 1,500,000 Scots will be living with the condition by 2030.

10 May 2012

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

Health law implementation news: Most red states slow walk health exchanges

Politico reports that most GOP-controlled states are holding off on building insurance exchanges until the Supreme Court issues its decision. Meanwhile, the Internal Revenue Service's ability to enforce the health law is the topic of a Capitol Hill hearing and a former White House advisor offers his views during a Madison speech.

20 Apr 2012

Possible link between sleep apnea and post-surgical delirium

An anecdotal observation of a possible link between sleep apnea and post-surgical delirium has been measured and confirmed by a team of researchers at the Duke University Medical Center.

28 Mar 2012

Vejthani Hospital offers Unicompartmental Knee Arthroplasty in Thailand

Vejthani Hospital Bangkok offers Unicompartmental Knee Arthroplasty to get better range of motion at Vejthani TJR center, the top international hospital in Thailand.

15 Mar 2012

FDA panel favors continued research on novel pain medicine

A panel of experts for the U.S. Food and Drugs Administration (FDA) this Monday recommended that the federal government should allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure.

13 Mar 2012

Abbott, GenLab collaborate to develop new assay for PLEX-ID automated microbial identification system

Abbott announced today it will collaborate with Genetics Laboratory, Inc. on the development of a molecular diagnostic test that will be designed to rapidly detect microorganisms that cause orthopedic infections.

5 Mar 2012

FDA takes more time to decide on the fate of BMS & Pfizer’s joint venture anticlotting drug Eliquis

The U.S FDA have pushed back the deadline for deciding whether to approve an experimental anticlotting drug developed jointly by Pfizer Inc. and Bristol-Myers Squibb Co. The companies said late Wednesday that the Food and Drug Administration has set a new target date of June 28 for deciding whether to approve Eliquis. That’s three months later than originally scheduled.

2 Mar 2012

FDA extends action date for Bristol-Myers Squibb, Pfizer's Eliquis NDA

Bristol-Myers Squibb Company and Pfizer announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

1 Mar 2012

First Edition: February 29, 2012

Today's headlines include reports on yesterday's GOP presidential primary elections and how health policy played a role in some of the rhetoric.

29 Feb 2012

FDA assigns Priority Review designation to JRD's XARELTO sNDA

Janssen Research & Development, LLC (JRD) announced today that the U.S. Food and Drug Administration (FDA) has assigned a Priority Review designation to the supplemental New Drug Application (sNDA) filed on December 29, 2011 for XARELTO (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS).

27 Feb 2012

Blue Belt's Navio PFS System receives CE Mark approval

Blue Belt Technologies, Inc., a medical device company focused on developing the next generation of "smart" surgical instruments providing precise robotic control for use initially in orthopedic procedures and then for other surgical specialties including neurosurgery, spinal and otolaryngology, announced today that it has received CE Mark for the Navio™ PFS System.

24 Feb 2012

Knee replacements double in 10 years, study says

More than 4 million Americans over 50 have artificial knees, according to a new study. ... "These data are sobering because we didn't know what an army of people we've created over the last decade," said study author Elena Losina, co-director of the Orthopedics and Arthritis Center for Outcomes Research at Harvard's Brigham and Women's Hospital. ... Artificial knees also wear out after a period of time, so as the operations are increasingly done on younger Americans, many will live long enough to almost certainly need a second or even third knee replacement.

14 Feb 2012

First Edition: February 13, 2012

Today's early morning highlights from the major news organizations preview President Barack Obama's budget, which will be released today, and examine the lingering controversy over mandates on contraceptive coverage.

13 Feb 2012

Bupivacaine may effectively manage pain after total knee replacement

Researchers at the Rothman Institute at Jefferson have shown that local anesthesia delivered through a catheter in the joint, intraarticularly, may be more beneficial than traditional opioids such as morphine and Oxycontin for pain management following total knee replacement surgery.

10 Feb 2012

TKR surgeries have more than doubled over the past decade

New research presented at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) found that more than 4.5 million Americans are living with a total knee replacement (TKR), as the number of TKR surgeries has more than doubled over the past decade, with the sharpest rise among younger patients. Osteoarthritis continues to be the primary reason for TKR.

10 Feb 2012

Shorter stay protocols for TKR patients may increase risk of mortality, readmission

No previous research has quantified and compared the costs and outcomes between total knee replacement (TKR) patients who have differing lengths of hospital stay following surgery.

10 Feb 2012